Johnson & Johnson (JNJ) Q1 FY26 earnings call

Johnson & Johnson reported a strong Q1 FY26, exceeding consensus and raising full-year guidance, driven by robust performance in Innovative Medicine and MedTech. The company is on track for $100 billion in annual revenue and maintains line of sight to double-digit growth by the end of the decade, fueled by its deep portfolio and pipeline. Strategic investments in innovation and new product launches are accelerating momentum, despite headwinds from STELARA biosimilar competition and increased launch-related expenses.